Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Farde

Showing results (61-70 of 218) with videos related to

Pageof 22
Sort By:
The International Journal of Neuropsychopharmacology|June 24, 2005
Support for limited brain availability of tyrosine in patients with schizophreniaLars Bjerkenstedt, Lars Farde, Lars Terenius, et al.
EJNMMI Research|December 1, 2018
Test-retest reliability and convergent validity of (R)-[<sup>11</sup>C]PK11195 outcome measures without arterial input functionPontus Plavén-Sigray, Granville James Matheson, Zsolt Cselényi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 2, 2018
PET imaging of [<sup>11</sup>C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter bindingKatarina Varnäs, Zsolt Cselényi, Aurelija Jucaite, et al.
The International Journal of Neuropsychopharmacology|May 10, 2001
A PET study ofLars Farde, Nathalie Ginovart, Christer Halldin, et al.
The International Journal of Neuropsychopharmacology|January 5, 2007
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopramJohan Lundberg, Jacob Strøyer Christophersen, Kamilla Buchberg Petersen, et al.
Human Brain Mapping|October 2, 2010
Extrastriatal dopamine D(2) receptor binding in Huntington's diseaseMouna Esmaeilzadeh, Lars Farde, Per Karlsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2016
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease PatientsIda Sonni, Patrik Fazio, Martin Schain, et al.
EJNMMI Research|July 23, 2017
Assessment of simplified ratio-based approaches for quantification of PET [<sup>11</sup>C]PBR28 dataGranville J Matheson, Pontus Plavén-Sigray, Anton Forsberg, et al.
Molecular Psychiatry|August 28, 2020
Serotonin transporter availability in adults with autism-a positron emission tomography studyMax Andersson, Ämma Tangen, Lars Farde, et al.
Neuroimage|January 10, 2012
Quantification of serotonin transporter availability with [11C]MADAM--a comparison between the ECAT HRRT and HR systemsMartin Schain, Miklós Tóth, Zsolt Cselényi, et al.
Pageof 22

Showing results (61-70 of 218) with videos related to

Sort By:
Pageof 22
The International Journal of Neuropsychopharmacology|June 24, 2005
Support for limited brain availability of tyrosine in patients with schizophreniaLars Bjerkenstedt, Lars Farde, Lars Terenius, et al.
EJNMMI Research|December 1, 2018
Test-retest reliability and convergent validity of (R)-[<sup>11</sup>C]PK11195 outcome measures without arterial input functionPontus Plavén-Sigray, Granville James Matheson, Zsolt Cselényi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 2, 2018
PET imaging of [<sup>11</sup>C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter bindingKatarina Varnäs, Zsolt Cselényi, Aurelija Jucaite, et al.
The International Journal of Neuropsychopharmacology|May 10, 2001
A PET study ofLars Farde, Nathalie Ginovart, Christer Halldin, et al.
The International Journal of Neuropsychopharmacology|January 5, 2007
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopramJohan Lundberg, Jacob Strøyer Christophersen, Kamilla Buchberg Petersen, et al.
Human Brain Mapping|October 2, 2010
Extrastriatal dopamine D(2) receptor binding in Huntington's diseaseMouna Esmaeilzadeh, Lars Farde, Per Karlsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2016
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease PatientsIda Sonni, Patrik Fazio, Martin Schain, et al.
EJNMMI Research|July 23, 2017
Assessment of simplified ratio-based approaches for quantification of PET [<sup>11</sup>C]PBR28 dataGranville J Matheson, Pontus Plavén-Sigray, Anton Forsberg, et al.
Molecular Psychiatry|August 28, 2020
Serotonin transporter availability in adults with autism-a positron emission tomography studyMax Andersson, Ämma Tangen, Lars Farde, et al.
Neuroimage|January 10, 2012
Quantification of serotonin transporter availability with [11C]MADAM--a comparison between the ECAT HRRT and HR systemsMartin Schain, Miklós Tóth, Zsolt Cselényi, et al.
Pageof 22